



U.S. Food & Drug Administration

Drugs



[Home](#) [Drugs](#) [Drug Safety and Availability](#)

## FDA Drug Safety Communication: Interactions between certain HIV or hepatitis C drugs and cholesterol-lowering statin drugs can increase the risk of muscle injury

[Safety Announcement](#)  
[Additional Information for Patients](#)  
[Additional Information for Healthcare Professionals](#)  
[Data Summary](#)  
[Statin Dose Limitations](#)  
[Reference](#)



Infographic About Cholesterol and Statins<sup>1</sup>

### Safety Announcement

**[3-01-2012]** The U.S. Food and Drug Administration (FDA) is issuing updated recommendations concerning drug-drug interactions between drugs for human immunodeficiency virus (HIV) or hepatitis C virus (HCV) known as protease inhibitors and certain cholesterol-lowering drugs known as statins. Protease inhibitors and statins taken together may raise the blood levels of statins and increase the risk for muscle injury (myopathy). The most serious form of myopathy, called rhabdomyolysis, can damage the kidneys and lead to kidney failure, which can be fatal.

The labels for both the HIV protease inhibitors and the affected statins have been updated to contain consistent information about the drug-drug interactions. These labels also have been updated to include dosing recommendations for those statins that may safely be co-administered with HIV or HCV protease inhibitors (see [Statin Dose Limitations](#) below).

Healthcare professionals should refer to the current drug labels for protease inhibitors and statins for the latest recommendations on prescribing these drugs.

Patients should contact their healthcare professional if they have any questions or concerns about taking protease inhibitors and statins.

### Additional Information for Patients

- Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) protease inhibitors can interact with cholesterol-lowering statins to increase the risk of muscle injury.
- Patients should inform their healthcare professional about all medicines that they are taking or plan to take prior to starting an HIV or HCV protease inhibitor or statin.
- HIV and HCV protease inhibitors should never be taken (are contraindicated) with lovastatin (Mevacor) and simvastatin (Zocor) (see [Statin Dose Limitations](#) below).
- Patients should contact their healthcare professional if they have any questions or concerns about HIV or HCV protease inhibitors or statins.
- Patients should report side effects from the use of HIV or HCV protease inhibitors and/or statins to the FDA MedWatch program, using the information in the "Contact FDA" box at the bottom of the page.

### Additional Information for Healthcare Professionals

- Co-administration of human immunodeficiency virus (HIV) or hepatitis C virus (HCV) protease inhibitors with certain statins can increase the risk of myopathy/rhabdomyolysis.
- Healthcare professionals should follow the recommendations in the drug labels when prescribing HIV or HCV protease inhibitors with statins (also see [Statin Dose Limitations](#) below).
- Healthcare professionals should report adverse events involving HIV or HCV protease inhibitors and/or statins to the FDA MedWatch program using the information in the "Contact FDA" box at the bottom of this page.

### Data Summary

#### Atorvastatin

The results from a drug-drug interaction study with atorvastatin and lopinavir/ritonavir that were previously in the atorvastatin label have not yet been validated. Therefore, these results have been removed from the label and the dose cap of atorvastatin 20 mg when co-administered with lopinavir/ritonavir has also been removed. Pending validation of the study, healthcare professionals should use caution when co-administering atorvastatin with lopinavir/ritonavir and use the lowest necessary dose of atorvastatin.

#### Lovastatin and simvastatin

Lovastatin and simvastatin are sensitive *in vivo* cytochrome P450 3A4 (CYP3A4) substrates. Therefore, strong CYP3A4 inhibitors are predicted to significantly increase lovastatin and simvastatin exposures. A literature review indicates that itraconazole, a strong CYP3A4 inhibitor, increases lovastatin exposure up to 20-fold, and the drug interaction appears to result in rhabdomyolysis.<sup>1</sup> Itraconazole increases simvastatin exposure up to 13-fold. Hence, other CYP3A4 inhibitors, including ketoconazole, posaconazole, erythromycin, clarithromycin, telithromycin, nefazodone, human immunodeficiency virus (HIV) protease inhibitors, and the hepatitis C virus (HCV) protease inhibitors boceprevir and telaprevir, are also expected to significantly increase lovastatin and simvastatin exposures. Therefore, concomitant administration of lovastatin and simvastatin with HIV protease inhibitors or HCV protease inhibitors (boceprevir and telaprevir) is contraindicated.

#### Rosuvastatin

The HIV protease inhibitor combinations lopinavir/ritonavir and atazanavir/ritonavir increase rosuvastatin exposure up to 3-fold. For these combinations, the dose of rosuvastatin should be limited to 10 mg.

**Statin Dose Limitations**

<b>Statin</b>	<b>Interacting protease inhibitor(s)</b>	<b>Prescribing recommendation</b>
Atorvastatin	▸ Tipranavir + ritonavir	Avoid atorvastatin
	▸ Telaprevir	
	▸ Lopinavir + ritonavir	Use with caution and use with the lowest atorvastatin dose necessary
	▸ Darunavir + ritonavir	
	▸ Fosamprenavir	Do not exceed 20 mg atorvastatin daily
	▸ Fosamprenavir + ritonavir	
	▸ Saquinavir + ritonavir	Do not exceed 40 mg atorvastatin daily
	▸ Nelfinavir	
Fluvastatin		No data available
Lovastatin	▸ HIV protease inhibitors	Contraindicated
	▸ Boceprevir	
	▸ Telaprevir	
Pitavastatin	▸ Atazanavir ± ritonavir	No dose limitations
	▸ Darunavir + ritonavir	
	▸ Lopinavir + ritonavir	
Pravastatin	▸ Darunavir + ritonavir	No dose limitations
	▸ Lopinavir + ritonavir	
Rosuvastatin	▸ Atazanavir ± ritonavir	Limit rosuvastatin dose to 10 mg once daily
	▸ Lopinavir + ritonavir	
Simvastatin	▸ HIV protease inhibitors	Contraindicated
	▸ Boceprevir	
	▸ Telaprevir	

HIV=human immunodeficiency virus

**Reference**

1. Lees RS, Lees AM. Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole. *N Engl J Med*. 1995;333:664-5.

**Related Information**

- [Statins](#)<sup>2</sup>

**Contact FDA**

1-800-332-1088

1-800-FDA-0178 Fax

Report a Serious Problem

[MedWatch Online](#)<sup>3</sup>

**Regular Mail:** Use postage-paid [FDA Form 3500](#)<sup>4</sup>

**Mail to:** MedWatch 5600 Fishers Lane

Rockville, MD 20857

**Links on this page:**

1. [/downloads/Drugs/DrugSafety/UCM293474.pdf](#)
2. [/Drugs/DrugSafety/InformationbyDrugClass/ucm294358.htm](#)
3. <https://www.accessdata.fda.gov/scripts/medwatch/medwatch-online.htm>
4. <http://www.fda.gov/downloads/Safety/MedWatch/DownloadForms/UCM082725.pdf>

- [Accessibility](#)
- [Contact FDA](#)
- [Careers](#)
- [FDA Basics](#)
- [FOIA](#)
- [No Fear Act](#)
- [Site Map](#)
- [Transparency](#)
- [Website Policies](#)

U.S. Food and Drug Administration  
10903 New Hampshire Avenue  
Silver Spring, MD 20993

Ph. 1-888-INFO-FDA (1-888-463-6332)

Email [FDA](#)



- [For Government](#)
- [For Press](#)
- [Combination Products](#)
- [Advisory Committees](#)
- [Science & Research](#)
- [Regulatory Information](#)
- [Safety](#)
- [Emergency Preparedness](#)
- [International Programs](#)
- [News & Events](#)
- [Training and Continuing Education](#)
- [Inspections/Compliance](#)
- [State & Local Officials](#)
- [Consumers](#)
- [Industry](#)
- [Health Professionals](#)



U.S. Department of Health & Human Services

---

**Links on this page:**

1. [/downloads/Drugs/DrugSafety/UCM293474.pdf](#)
2. [/Drugs/DrugSafety/InformationbyDrugClass/ucm294358.htm](#)
3. <https://www.accessdata.fda.gov/scripts/medwatch/medwatch-online.htm>
4. <http://www.fda.gov/downloads/Safety/MedWatch/DownloadForms/UCM082725.pdf>